Impact Biomedical Announces Reverse Stock Split Ahead of Zoar Merger

Impact Biomedical Inc. announced a 1-for-12.62 reverse stock split to pursue the completion of its merger with Zoar Limited. The Company's Board of Directors approved the reverse stock split, which will become effective on September 23, 2026. The stock will continue to trade on NYSE American Exchange under the ticker symbol "IBO" and a new CUSIP number will be assigned. The reverse stock split aims to support the Company's efforts in connection with the proposed business combination transaction and its continued-listing objectives.